Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by-nc (c) Dimopoulos, Meletios A. et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/206695

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Renal impairment (RI) is a relatively common complication of multiple myeloma, which increases in frequency as disease becomes more advanced and recovery of renal function becomes less likely as patients progress through lines of therapy. Clinical trials in the relapsed/refractory multiple myeloma (RRMM) setting have not uniformly included patients with RI or robustly reported their outcomes. Here, we review existing data among patients with RI and RRMM across drug classes (including immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, antibody-drug conjugates, chimeric antigen receptor T-cell therapies, and exportin-1 inhibitor) to provide an improved understanding of available treatment options for this important population. We highlight data from pivotal clinical trials, including data relating to renal response (as defined by the International Myeloma Working Group) and discuss real-world experiences in patients with RI, where applicable. Despite substantial advances in RRMM treatment, the presence of RI remains associated with reduced overall survival. Consistent inclusion of patients with RI, and uniform reporting of their outcomes, should be encouraged in future prospective trials of treatments for RRMM.

Citació

Citació

DIMOPOULOS, Meletios a., MIKHAEL, Joseph, TERPOS, Evangelos, LELEU, Xavier, MOREAU, Philippe, BLADÉ, J. (joan), KIM, Jin seok, STOCKERL GOLDSTEIN, Keith, RICHARDSON, Paul g.. An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. _Therapeutic Advances In Hematology_. 2022. Vol. 13, núm. 20406207221088458. [consulta: 20 de gener de 2026]. ISSN: 2040-6215. [Disponible a: https://hdl.handle.net/2445/206695]

Exportar metadades

JSON - METS

Compartir registre